Sugi Predict

Sugi Predict / Compounds / SCHEMBL5598729

SCHEMBL5598729

SCHEMBL5598729

CN1C(c2ccccc2)CC(=O)CC1c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.59
▸ ATM Q13315 1/20 0.59
▸ CHRNA7 P36544 2/20 0.50
▸ CHRNB2 P17787 1/20 0.50
▸ CHRNB4 P30926 1/20 0.50
▸ CHRNA3 P32297 1/20 0.50
▸ CHRNA4 P43681 1/20 0.50
▸ BRD4 O60885 3/20 0.47
▸ TSHR P16473 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ MAPT P10636 2/20 0.45
▸ GAA P10253 1/20 0.45
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.44
▸ LMNA P02545 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11970774 1.00 ALDH1A1 (0.59) ALDH1A1ATMCHRNA7CHRNB2CHRNB4
SCHEMBL5598942 0.82 MEN1 (0.43) ALDH1A1ATMCHRNA7KMT2AMAOA
SCHEMBL1490873 0.80 L3MBTL1 (0.41) ALDH1A1ATMTSHRMAPTGAA
SCHEMBL17225911 0.80 ESR2 (0.51) ALDH1A1ATMKMT2AMAPTMAOA
SCHEMBL14606142 0.79 GAA (0.45) ALDH1A1ATMCHRNA7CHRNB2CHRNB4
SCHEMBL1490988 0.78 KDM4E (0.59) ALDH1A1CHRNA7CHRNB2CHRNB4CHRNA3
SCHEMBL5598828 0.78 EGFR (0.44) KMT2ACYP2D6
SCHEMBL14423680 0.78 CHRNA7 (0.57) ALDH1A1ATMCHRNA7CHRNB2CHRNB4
SCHEMBL13206668 0.78 CHRNA7 (0.57) ALDH1A1ATMCHRNA7CHRNB2CHRNB4
SCHEMBL16093481 0.78 GAA (0.44) ALDH1A1ATMCHRNA7CHRNB2CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255853-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2025-08-14 — — US disclosed
US-20240285592-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2024-08-29 — — US disclosed
US-11951099-B2 Methods for treating plasma cell neoplasm with human therapeutic agents ANKH LIFE SCIENCES LIMITED (IE) 2024-04-09 — — US disclosed
CN-107106519-B Therapeutic agent for human 安克生命科学公司 2023-01-24 — — CN disclosed
CN-115569136-A Therapeutic agent for human 安克生命科学公司 2023-01-06 — — CN disclosed
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2022-05-19 — — US disclosed
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2022-05-19 — — US disclosed
US-11266634-B2 Methods for treating melanoma with human therapeutic agents ANKH LIFE SCIENCES LIMITED (IE) 2022-03-08 — — US disclosed
US-20200383958-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2020-12-10 — — US disclosed
US-20200383958-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2020-12-10 — — US disclosed
US-8841326-B2 Therapeutic curcumin derivatives STC.UNM (US) 2014-09-23 — — US disclosed
US-8841326-B2 Therapeutic curcumin derivatives STC.UNM (US) 2014-09-23 — — US disclosed
US-8841326-B2 Therapeutic curcumin derivatives STC.UNM (US) 2014-09-23 — — US disclosed
US-20120214996-A1 COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-08-23 — — US disclosed
US-20120214996-A1 COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-08-23 — — US disclosed
WO-2011033115-A2 COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-03-24 — — WO disclosed
US-20070060644-A1 Therapeutic curcumin derivatives STC.UNM 2007-03-15 — — US disclosed
US-20070060644-A1 Therapeutic curcumin derivatives STC.UNM 2007-03-15 — — US disclosed
US-20070060644-A1 Therapeutic curcumin derivatives STC.UNM 2007-03-15 — — US disclosed
US-20060276536-A1 Cancer treatment using curcumin derivatives STC.UNM 2006-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11266634-B2 Methods for treating melanoma with human therapeutic agents HNMT, INMT, TYR ALDH1A1 284/4885ATM 3702/4885CHRNA7 2824/4885
US-11951099-B2 Methods for treating plasma cell neoplasm with human therapeutic agents MCL1, CD44, INMT ALDH1A1 957/4885ATM 3956/4885CHRNA7 4577/4885
US-20070060644-A1 Therapeutic curcumin derivatives FABP2, GLS2, FABP1 ALDH1A1 670/4885ATM 3595/4885CHRNA7 4224/4885
US-20240285592-A1 HUMAN THERAPEUTIC AGENTS INMT, NLN, MYC ALDH1A1 1257/4885ATM 2737/4885CHRNA7 1792/4885
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN ALDH1A1 371/4885ATM 3094/4885CHRNA7 3136/4885
US-20200383958-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN ALDH1A1 371/4885ATM 3094/4885CHRNA7 3136/4885
US-20120214996-A1 COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES TST, PDXK, TBCB ALDH1A1 1763/4885ATM 3721/4885CHRNA7 4693/4885
US-20250255853-A1 HUMAN THERAPEUTIC AGENTS HASPIN, TIPARP, SHARPIN ALDH1A1 1381/4885ATM 2329/4885CHRNA7 3502/4885
US-20060276536-A1 Cancer treatment using curcumin derivatives BRCA1, VHL, TP53 ALDH1A1 110/4885ATM 727/4885CHRNA7 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.